Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Harding

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Journal of Virology|February 6, 2009
Novel immunocompetent murine tumor model for evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectorsMichael Robinson, Betty Li, Ying Ge, et al.
Cancer Research|June 3, 2005
Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vesselsYulong He, Iiro Rajantie, Katri Pajusola, et al.
Journal of Advanced Nursing|November 27, 2008
Stages of Change--continuous measure (URICA-E2): psychometrics of a Norwegian versionAnners Lerdal, Britt Moe, Elin Digre, et al.
Medical Physics|October 27, 2023
Deep learning-based ultrasound auto-segmentation of the prostate with brachytherapy implanted needlesPrakash Hampole, Thomas Harding, Derek Gillies, et al.
Journal of Molecular and Cellular Cardiology|June 24, 2003
Third-generation lentivirus vectors efficiently transduce and phenotypically modify vascular cells: implications for gene therapyKate L Dishart, Laura Denby, Sarah J George, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2026
HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic ImplicationsKalyan Banda, Helen R Davies, Yogesh Kumar, et al.
JAMA Oncology|October 14, 2021
Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With RucaparibTanya T Kwan, Amit M Oza, Anna V Tinker, et al.
The Bone & Joint Journal|April 30, 2026
The epidemiology and outcomes of periprosthetic femur fractures : the Scottish National Audit of Periprosthetic Femur Fractures (SNAP Femur) studyMatthew J Kennedy, Nick D Clement, Luke Farrow, et al.
Gynecologic Oncology|March 23, 2021
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2Gottfried E Konecny, Amit M Oza, Anna V Tinker, et al.
Nature Communications|May 4, 2021
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)Elizabeth M Swisher, Tanya T Kwan, Amit M Oza, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Journal of Virology|February 6, 2009
Novel immunocompetent murine tumor model for evaluation of conditionally replication-competent (oncolytic) murine adenoviral vectorsMichael Robinson, Betty Li, Ying Ge, et al.
Cancer Research|June 3, 2005
Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vesselsYulong He, Iiro Rajantie, Katri Pajusola, et al.
Journal of Advanced Nursing|November 27, 2008
Stages of Change--continuous measure (URICA-E2): psychometrics of a Norwegian versionAnners Lerdal, Britt Moe, Elin Digre, et al.
Medical Physics|October 27, 2023
Deep learning-based ultrasound auto-segmentation of the prostate with brachytherapy implanted needlesPrakash Hampole, Thomas Harding, Derek Gillies, et al.
Journal of Molecular and Cellular Cardiology|June 24, 2003
Third-generation lentivirus vectors efficiently transduce and phenotypically modify vascular cells: implications for gene therapyKate L Dishart, Laura Denby, Sarah J George, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2026
HRDetect in Tubo-ovarian Carcinoma: Stratification and Therapeutic ImplicationsKalyan Banda, Helen R Davies, Yogesh Kumar, et al.
JAMA Oncology|October 14, 2021
Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With RucaparibTanya T Kwan, Amit M Oza, Anna V Tinker, et al.
The Bone & Joint Journal|April 30, 2026
The epidemiology and outcomes of periprosthetic femur fractures : the Scottish National Audit of Periprosthetic Femur Fractures (SNAP Femur) studyMatthew J Kennedy, Nick D Clement, Luke Farrow, et al.
Gynecologic Oncology|March 23, 2021
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2Gottfried E Konecny, Amit M Oza, Anna V Tinker, et al.
Nature Communications|May 4, 2021
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)Elizabeth M Swisher, Tanya T Kwan, Amit M Oza, et al.
Pageof 3